AI model can predict chemotherapy benefit in breast cancer

Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early-stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short- and long-term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit and which are not.